Aripiprazole for the treatment of bipolar disorder: A review of current evidence

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 3, 2011, Pages 473-488

  Fagiolini, Andrea ^a   Nitti, Maria ^a   Forgione, Rocco N ^a   Marra, Francesco S ^b   Casamassima, Francesco ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

aripiprazole; bipolar depression; bipolar disorder; mania

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LITHIUM; LORAZEPAM; PLACEBO; PROLACTIN; SEROTONIN 2A RECEPTOR; VALPROIC ACID;

ACCIDENTAL INJURY; ADJUVANT THERAPY; AGITATION; AKATHISIA; ANXIETY; AUTISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MANIA; META ANALYSIS (TOPIC); MIXED ANXIETY AND DEPRESSION; MULTICENTER STUDY (TOPIC); MUSCLE RIGIDITY; NAUSEA; NERVOUSNESS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RELAPSE; REMISSION; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAMUSCULAR; PIPERAZINES; QUINOLONES;

EID: 79251491071     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.552429     Document Type: Review

References (52)

1. Dillenschneider A, Raymond S, McQUade RD, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, placebo-and haloperidol-controlled study (CN138-162). Eur Arch Psychiatry Clin Neurosci 2007;257(Suppl 2):35
2. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-8
3. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20(4):536-46
4. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
5. Vieta E, Loze JY, T'Joen C, et al. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Poster presented at WEBP, Strasbourg, France, 13-15 December, 2007
6. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-37
7. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91
8. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36
9. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62(11):841-2
10. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9
11. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-40
12. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483(1):45-53
13. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1(2):141-7
14. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
15. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18(3):375-83
16. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27(2):248-59
17. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493(1-3):75-83
18. Mamo D, GraffA, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry2007;164(9):1411-17
19. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26(5):649-66
20. Wood MD, Scott C, Clarke K, et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006;546(1-3):88-94
21. Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007;8(6):612-22
22. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40(1):77-97
23. Abilify: US prescribing information. Available from: www.abilify. comrevision11/2009 [Last accessed 18 October 2010]
24. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007;68(9):1377-83
25. Suppes T, Eudicone J, McQuade R, et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008;107(1-3):145-54
26. Garcia-Amador M, Pacchiarotti I, Valenti M, et al. Role of aripiprazole in treating mood disorders. Expert Rev Neurother 2006;6(12):1777-83
27. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27(2):171-6
28. Boulton DW, Kollia G, Mallikaarjun S, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008;47(7):475-85
29. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo-and haloperidol-controlled study. Br J Psychiatry 2009;194(1):40-8
30. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo-and lithium-controlled study. J Affect Disord 2009;112(1-3):36-49
31. Ketter TA, Wang PW, Chandler RA, et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006;18(3): 169-72
32. Kemp DE, Dago PL, Straus JL, et al. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. J Clin Psychopharmacol 2007;27(3):304-5
33. Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):574-7
34. McElroy SL, Suppes T, Frye MA, et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 2007;101(1-3):275-81
35. Dunn RT, Stan VA, Chriki LS, et al. A prospective, open-label study of Aripiprazole mono-and adjunctive treatment in acute bipolar depression. J Affect Disord 2008;110(1-2):70-4
36. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28(1):13-20
37. Quante A, Zeugmann S, Luborzewski A, et al. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol 2010;25(2):126-32
38. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008;62(5):679-87
39. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16
40. Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009;31(5):478-83
41. Fountoulakis KN, Gonda X, Vieta E, Schmidt F. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry 2009;8:27
42. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
43. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
44. Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008;59(10):1175-83
45. Sachs GS, Gardner-Schuster EE. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl 2007;(434):27-34
46. McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 2010;19(12):1527-44
47. Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin 2006;22(11):2209-19
48. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328(19):1398-405
49. Ciraulo DA, Nace EP. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 2000;9(4):276-9, discussion 280-274
50. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10(1):12-21
51. Pfeffer G, Chouinard G, Margolese HC Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005;20(3):179-81
52. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68(Suppl 6):5-9